New CAR t cocktail aims to tackle Hard-to-Treat myeloma
NCT ID NCT04855136
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a CAR T cell therapy called bb2121 (ide-cel) combined with other drugs in 21 adults with relapsed or refractory multiple myeloma. The goal was to find a safe dose and see if the combinations could shrink tumors. The study was terminated early, so results are limited, but it provides initial safety and effectiveness data for these combination approaches.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bb2121 (ide-cel) CAR T cell therapy combined with CC-220 or BMS-986405
What this could lead to
If successful, this could point toward a more effective treatment option for patients with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is an early, small trial (21 participants) that was terminated, so results are limited. CAR T therapy carries risks like severe immune reactions and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 101
Jacksonville, Florida, 32224-1865, United States
-
Local Institution - 103
Nashville, Tennessee, 37203, United States
-
Local Institution - 104
Atlanta, Georgia, 30322, United States
-
Local Institution - 107
Houston, Texas, 77030, United States
-
Local Institution - 108
Boston, Massachusetts, 02117, United States
-
Local Institution - 109
Hackensack, New Jersey, 07601, United States
-
Local Institution - 110
New York, New York, 10032, United States
-
Local Institution - 111
Charlotte, North Carolina, 28204, United States
-
Local Institution - 113
San Francisco, California, 94143, United States
-
Local Institution - 114
Chicago, Illinois, 60611, United States
-
Local Institution - 117
Birmingham, Alabama, 10016, United States
-
Local Institution - 118
Philadelphia, Pennsylvania, 19107, United States
-
Local Institution - 120
Atlanta, Georgia, 30342, United States
-
Local Institution - 124
Boston, Massachusetts, 02215, United States
-
Local Institution - 201
Pamplona, 31008, Spain
-
Local Institution - 202
Salamanca, 37007, Spain
-
New York University Langone
New York, New York, 10016, United States